antihemophilic factor

(redirected from Advate)
Also found in: Dictionary, Thesaurus, Medical.

antihemophilic factor

[¦an·tē‚hē·mə′fil·ik ‚fak·tər]
(biochemistry)
A soluble protein clotting factor in mammalian blood. Also known as factor VIII; thromboplastinogen.
References in periodicals archive ?
These collaborations focus on further advancing ADVATE, with the objective of reducing the frequency of infusions and enhancing quality of life for hemophilia patients.
This launch follows the US Food and Drug Administration's (FDA) approval of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on full-length ADVATE [Antihemophilic Factor (Recombinant)].
Comments: BioScience revenues were $1.7 billion, up 8%, driven primarily by double-digit growth and continued strong demand for hemophilia therapies (+11% to $942 million), including ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] and FEIBA (an inhibitor therapy).
Baxter International achieved positive results from its Phase III trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE, which met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis arm compared to the on-demand arm.
M2 PHARMA-April 25, 2014-Baxter wins US FDA's approval for ADVATE with BAXJECT III reconstitution system for treating patients with hemophilia A
M2 EQUITYBITES-April 25, 2014-Baxter wins US FDA's approval for ADVATE with BAXJECT III reconstitution system for treating patients with hemophilia A
The current suite supports the processing of ADVATE [Antihemophilic Factor (Recombinant)], the company's recombinant factor VIII (rFVIII) for the treatment of patients with hemophilia A.
It was designed based on the full-length ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] molecule.
Marketer 1 Humira Abbott 2 Remicade J&J 3 Rituxan Roche Genentech 4 Enbrel Amgen 5 Lantus Sanofi 6 Herceptin Roche Genentech 7 Avastin Roche Genentech 8 Neulasta Amgen 9 Lucentis Roche Genentech 10 Prevnar 13 Pfizer 11 Epogen/Procrit Amgen; J&J 12 NovoLog Novo Nordisk 13 Avonex Biogen IDEC 14 Humalog Lilly 15 Rebif Merck KGaA 16 Pegasys Roche 17 Aranesp Amgen 18 Advate Baxter 19 Victoza Novo Nordisk 20 Levemir Novo Nordisk 21 Novolin Novo Nordisk 22 Botox Allergan 23 Erbitux BMS 24 Eylea/Zaltrap Regeneron 25 Gardasil Merck & Co.
M2 PHARMA-December 19, 2011-Baxter's ADVATE gets FDA approval for prophylaxis of Hemophilia A in adults, children(C)2011 M2 COMMUNICATIONS